Executive record

Jay S. Stout, Ph.D.

Public governance roles and source-backed Claims for this individual.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:jay-s-stout-ph-d-imvtVersion: public-0As of: 2026-09-30

Not yet claimed8 published Claims2 sources

Key Claims

Biography

Dr. Stout has served as Chief Technology Officer since April 2023, with extensive experience in Technical Operations across immunology, cell and gene therapy, and oncology at companies including Immunomedics, Merck, Amgen, and Pfizer. He has served on the Amgen Center for BioProcessing Advisory Board at Keck Graduate Institute for over 10 years.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Executive career

  1. 2025 to end not publishedExecutive title: Chief Technology Officer · Organization not publishedIMVT DEF 14A executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. IMVT DEF 14A executive officers

    sec filing · Source published: Jul 9, 2025 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Executive company: Executive at Immunovant Inc · Claim reviewed: May 15, 2026
    • Executive title: Executive title: Chief Technology Officer · Claim reviewed: May 15, 2026
    • Technology background: Technology background reported in filings · Claim reviewed: May 15, 2026

  2. IMVT executive roster source

    sec filing · Source published: Date unavailable · Retrieved: May 3, 2026

    Supports 5 claims
    • AI expertise: AI expertise reported in filings · Claim reviewed: May 3, 2026
    • AI governance relevance: AI governance relevance reported from role and filings · Claim reviewed: May 3, 2026
    • Executive company: Executive at Immunovant Inc · Claim reviewed: May 15, 2026
    • Executive function: Technology Data Product (CTO) · Claim reviewed: May 3, 2026
    • Executive title: Executive title: Chief Technology Officer · Claim reviewed: May 15, 2026